Published in J Autoimmun on February 01, 1988
Genetic aspects of Sjögren's syndrome. Arthritis Res (2002) 1.30
HLA class II phenotype controls diversification of the autoantibody response in primary Sjögren's syndrome (pSS). Clin Exp Immunol (1998) 0.97
Epitope mapping with synthetic peptides of 52-kD SSA/Ro protein reveals heterogeneous antibody profiles in human autoimmune sera. Clin Exp Immunol (1994) 0.89
Advances in the Aetiophatogenesis of Sjögren's Syndrome: a Literature Review. J Oral Maxillofac Res (2012) 0.80
Contribution of Genetic Factors to Sjögren's Syndrome and Sjögren's Syndrome Related Lymphomagenesis. J Immunol Res (2015) 0.78
Anti-Ro (SSA)/La (SSB) antibodies and Sjögren's syndrome. Clin Rheumatol (1990) 0.78
Classification criteria for Sjögren's syndrome: a revised version of the European criteria proposed by the American-European Consensus Group. Ann Rheum Dis (2002) 20.48
Preliminary criteria for the classification of Sjögren's syndrome. Results of a prospective concerted action supported by the European Community. Arthritis Rheum (1993) 7.14
Immune interferon in the circulation of patients with autoimmune disease. N Engl J Med (1979) 5.58
Increased risk of lymphoma in sicca syndrome. Ann Intern Med (1978) 4.63
Rheumatoid arthritis in Greek and British patients. A comparative clinical, radiologic, and serologic study. Arthritis Rheum (1992) 3.92
Sjögren's syndrome (Sicca syndrome): current issues. Ann Intern Med (1980) 3.81
Assessment of the European classification criteria for Sjögren's syndrome in a series of clinically defined cases: results of a prospective multicentre study. The European Study Group on Diagnostic Criteria for Sjögren's Syndrome. Ann Rheum Dis (1996) 3.68
Remission of proliferative lupus nephritis following B cell depletion therapy is preceded by down-regulation of the T cell costimulatory molecule CD40 ligand: an open-label trial. Arthritis Rheum (2005) 3.25
Malignant lymphoma in primary Sjögren's syndrome: a multicenter, retrospective, clinical study by the European Concerted Action on Sjögren's Syndrome. Arthritis Rheum (1999) 2.99
Disparities in rheumatoid arthritis disease activity according to gross domestic product in 25 countries in the QUEST-RA database. Ann Rheum Dis (2009) 2.61
European multicentre study to define disease activity criteria for systemic sclerosis. II. Identification of disease activity variables and development of preliminary activity indexes. Ann Rheum Dis (2001) 2.49
Mycophenolate mofetil as first-line treatment improves clinically evident early scleroderma lung disease. Rheumatology (Oxford) (2006) 2.17
Demonstration of activation of B lymphocytes in New Zealand black mice at birth by an immunoradiometric assay for murine IgM. J Immunol (1977) 2.06
The European Community Study Group on diagnostic criteria for Sjögren's syndrome. Sensitivity and specificity of tests for ocular and oral involvement in Sjögren's syndrome. Ann Rheum Dis (1994) 2.03
Genetic differences between primary and secondary sicca syndrome. N Engl J Med (1979) 1.93
Differences in the clinical manifestations of sicca syndrome in the presence and absence of rheumatoid arthritis. Am J Med (1979) 1.79
Clinical evolution, and morbidity and mortality of primary Sjögren's syndrome. Semin Arthritis Rheum (2000) 1.74
Multiple interferons in the circulation of patients with systemic lupus erythematosus and vasculitis. Arthritis Rheum (1982) 1.73
Effects of infliximab treatment on insulin resistance in patients with rheumatoid arthritis and ankylosing spondylitis. Ann Rheum Dis (2004) 1.73
Patients with anticentromere antibodies, clinical features, diagnoses and evolution. Br J Rheumatol (1993) 1.64
Efficacy and safety of the fully human anti-tumour necrosis factor alpha monoclonal antibody adalimumab (D2E7) in DMARD refractory patients with rheumatoid arthritis: a 12 week, phase II study. Ann Rheum Dis (2003) 1.64
Hypokalaemic paralysis as the presenting manifestation of primary Sjögren's syndrome. Nephrol Dial Transplant (1994) 1.62
High prevalence of anti-cardiolipin and other autoantibodies in a healthy elderly population. Clin Exp Immunol (1987) 1.59
Radiographic evidence of disease progression in methotrexate treated and nonmethotrexate disease modifying antirheumatic drug treated rheumatoid arthritis patients: a meta-analysis. J Rheumatol (1992) 1.56
Anti-Ro(SSA) positive rheumatoid arthritis (RA): a clinicoserological group of patients with high incidence of D-penicillamine side effects. Ann Rheum Dis (1985) 1.56
Anti-signal recognition particle autoantibodies: marker of a necrotising myopathy. Ann Rheum Dis (2006) 1.54
Lymphoma development in Sjögren's syndrome: novel p53 mutations. Arthritis Rheum (1999) 1.53
Sjögren's syndrome in patients with the CREST variant of progressive systemic scleroderma. J Rheumatol (1991) 1.51
Remission, relapse, and re-remission of proliferative lupus nephritis treated with cyclophosphamide. Kidney Int (2000) 1.50
Demonstration of circulating immune complexes in Sjögren's syndrome. J Immunol (1979) 1.46
Increased expression of the FoxP3 functional marker of regulatory T cells following B cell depletion with rituximab in patients with lupus nephritis. Clin Immunol (2007) 1.44
Increased prevalence of anti-thyroid antibodies in patients with limited scleroderma. Scand J Rheumatol (2011) 1.41
Induction of psoriatic skin lesions in a patient with rheumatoid arthritis treated with rituximab. Clin Exp Rheumatol (2010) 1.40
Investigation for the presence of anti-erythropoietin antibodies in patients with myelodysplastic syndromes. Eur J Haematol (2001) 1.40
The Th1/Th2 cytokine balance changes with the progress of the immunopathological lesion of Sjogren's syndrome. Clin Exp Immunol (2002) 1.39
Antiphospholipid syndrome: clinical and therapeutic aspects. Lupus (1994) 1.39
Necrotizing vasculitis in Greece: clinical, immunological and immunogenetic aspects. A study of 66 patients. Br J Rheumatol (1997) 1.39
Uterine cervical involvement in a patient with Wegener's granulomatosis. Am J Med (2000) 1.38
Respiratory manifestations in primary Sjögren's syndrome. A clinical, functional, and histologic study. Chest (1985) 1.37
Preliminary diagnostic criteria for Sjögren's syndrome. Scand J Rheumatol Suppl (1986) 1.37
Laryngeal involvement in rheumatoid arthritis. Rheumatol Int (2005) 1.36
Clinically significant and biopsy-documented renal involvement in primary Sjögren syndrome. Medicine (Baltimore) (2000) 1.36
Immune-mediated skin lesions in patients treated with anti-tumour necrosis factor alpha inhibitors. Scand J Rheumatol (2009) 1.34
Kidney involvement in primary Sjögren's syndrome. Scand J Rheumatol Suppl (1986) 1.33
Sjögren's syndrome association with HLA-Dw3. N Engl J Med (1977) 1.32
Diffuse fasciitis with eosinophilia. A clinicopathologic study. Am J Med (1980) 1.31
Sjögren's syndrome: a defect in reticuloendothelial system Fc-receptor-specific clearance. Ann Intern Med (1979) 1.29
Sjögren-type syndrome after allogeneic bone-marrow transplantation. Ann Intern Med (1977) 1.27
Central nervous system involvement in Sjogren's syndrome. Ann Rheum Dis (2004) 1.26
HLA-DR expression by labial minor salivary gland tissues in Sjögren's syndrome. Ann Rheum Dis (1986) 1.25
Epidemiology of primary Sjögren's syndrome in north-west Greece, 1982-2003. Rheumatology (Oxford) (2005) 1.23
Mixed monoclonal cryoglobulinemia and monoclonal rheumatoid factor cross-reactive idiotypes as predictive factors for the development of lymphoma in primary Sjögren's syndrome. Arthritis Rheum (1996) 1.23
Ribosomal P autoantibodies in systemic lupus erythematosus. Frequencies in different ethnic groups and clinical and immunogenetic associations. Arthritis Rheum (1996) 1.23
Occult connective tissue diseases mimicking idiopathic interstitial pneumonias. Eur Respir J (2008) 1.21
Polyclonally triggered B cells in the peripheral blood and bone marrow of normal individuals and in patients with systemic lupus erythematosus and primary Sjögren's syndrome. Arthritis Rheum (1981) 1.21
Prevalence and outcome of pulmonary fibrosis in microscopic polyangiitis. Eur Respir J (2009) 1.21
Sjögren's syndrome in patients with primary biliary cirrhosis. Hepatology (1990) 1.19
Expression of functional Toll-like receptors by salivary gland epithelial cells: increased mRNA expression in cells derived from patients with primary Sjögren's syndrome. Clin Exp Immunol (2007) 1.17
T cell subpopulations in the labial minor salivary gland histopathologic lesion of Sjögren's syndrome. J Rheumatol (1991) 1.17
Role of cytokines in the pathogenesis of anemia of chronic disease in rheumatoid arthritis. Clin Immunol (1999) 1.17
The role of microRNA-146a (miR-146a) and its target IL-1R-associated kinase (IRAK1) in psoriatic arthritis susceptibility. Scand J Immunol (2010) 1.15
Brucella arthritis. Scand J Rheumatol (1986) 1.15
Presence of systemic autoimmune disorders in patients with autoimmune thyroid diseases. Ann Rheum Dis (2004) 1.14
Dermatomyositis in a patient with adenocarcinoma of the gall bladder. Ann Rheum Dis (2002) 1.14
Scleroderma, Sjögren-like syndrome, and chronic graft-versus-host disease. Ann Intern Med (1977) 1.14
Pulmonary involvement in patients with early rheumatoid arthritis. Scand J Rheumatol (2007) 1.13
Does cigarette smoking influence disease expression, activity and severity in early rheumatoid arthritis patients? Clin Exp Rheumatol (2006) 1.12
Efficacy and safety of switching from infliximab to adalimumab: a comparative controlled study. Ann Rheum Dis (2005) 1.12
Clinical characteristics of patients with myositis and autoantibodies to different fragments of the Mi-2 beta antigen. Ann Rheum Dis (2006) 1.12
Risk factors for central nervous system involvement in systemic lupus erythematosus. QJM (2000) 1.12
CBA/N X-linked B-cell defect prevents NZB B-cell hyperactivity in F1 mice. J Exp Med (1979) 1.12
Outcome of lupus pregnancy: a controlled study. Rheumatology (Oxford) (2000) 1.12
Erythema nodosum: the underlying conditions. Clin Rheumatol (2000) 1.11
Renal tubular acidosis in primary Sjögren's syndrome. Clin Rheumatol (1992) 1.11
Cytokine mRNA expression in the labial salivary gland tissues from patients with primary Sjögren's syndrome. Br J Rheumatol (1995) 1.10
Incomplete lupus erythematosus: results of a multicentre study under the supervision of the EULAR Standing Committee on International Clinical Studies Including Therapeutic Trials (ESCISIT). Rheumatology (Oxford) (2001) 1.10
Detection of anti-interferon antibodies in systemic lupus erythematosus. Clin Exp Rheumatol (1985) 1.10
Liver involvement in primary Sjögren's syndrome. Br J Rheumatol (1994) 1.09
Demonstration and identification of monoclonal proteins in the urine of patients with Sjögren's syndrome. Ann Rheum Dis (1985) 1.09
Autoimmune phenomena in myelodysplastic syndromes: a 4-yr prospective study. Rheumatology (Oxford) (2004) 1.09
Expression of B7 costimulatory molecules by salivary gland epithelial cells in patients with Sjögren's syndrome. Arthritis Rheum (1999) 1.09